Medtronic shrugs off scandal to post improved results
This article was originally published in Clinica
In spite of hiccups in Germany Medtronic (US) managed to increase sales and profits by over 25% in fiscal 1995 (ended April 30th). Total revenues were $1,740 million, compared with $1,390 million last year, and net earnings were up 26.5% at $294 million.
You may also be interested in...
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.
Momenta Pharmaceuticals has agreed to pay $35.0m to settle claims that it manipulated generic approval processes in the US to shut competitor Amphastar out of the US enoxaparin market.